Abstract
Withaferin A is one defined steroidal lactone found in Withania somnifera, the plant commonly called ashwagandha. Total withanolides is a group assay: it combines multiple related molecules whose proportions depend on plant part, extraction and analytical method. The terms are not interchangeable. The formulation brief specified 18 mg of nominal 99% Withaferin A, and Geroprotect’s current Formula page lists Withaferin A at 18 mg in Essentials II. That is the design intent, not a finished-batch measurement. The supplier raw-material document reviewed for this note instead describes an ashwagandha extract assayed at 5.21% total withanolides; it does not report a Withaferin A-specific assay.
The arithmetic is simple but conditional. If 18 mg of that documented extract was used, 18 × 0.0521 equals 0.9378 mg—about 0.94 mg—of total withanolides. It does not equal 0.94 mg of Withaferin A, because the fraction of that total attributable to Withaferin A is unknown. A supplier raw-material certificate also does not, by itself, prove which material entered a finished batch, how much entered it or what a finished-product assay would find. This is therefore a specification explanation, not a retrospective finished-batch test.
The scientific reason for studying Withaferin A remains interesting. Cell and animal work places it around vimentin, Hsp90, the proteasome, NF-κB, Nrf2 and metabolic signalling. Those findings are preclinical and often arise in cancer or injury models at pharmacological exposures. Human evidence mainly concerns chemically complex ashwagandha extracts, including one small phase I study of an extract containing 4.5% Withaferin A. It does not establish a human healthy-aging effect for isolated Withaferin A or for Essentials II.
01 · Identity and arithmetic
The molecule, the mixture and the 18 mg question
Withaferin A is a single withanolide. Ashwagandha contains many withanolides and withanosides, including Withaferin A, withanolide A, withanolide B, withanone and several glycosides. A validated UHPLC method developed to resolve eleven of them illustrates why a botanical extract needs a chemical profile rather than one family name.1 The relative composition also changes with plant part and extraction. Two materials can both satisfy a “total withanolides” declaration while containing different individual molecules.
The reviewed supplier raw-material certificate names roots and aerial parts and reports 5.21% total withanolides. It does not give a Withaferin A-specific percentage. That distinction prevents three common but incorrect substitutions:
- “5.21% total withanolides” does not mean “5.21% Withaferin A.”
- “18 mg of extract” does not mean “18 mg of Withaferin A.”
- A raw-material assay does not establish the composition of a finished tablet without traceability and finished-batch evidence.
| Input | Calculation | What it means |
|---|---|---|
| Public formula declaration | Withaferin A · 18 mg | The intended named ingredient and amount in Essentials II. |
| Supplier raw-material document | Ashwagandha extract · 5.21% total withanolides | A group assay for the documented raw material; no Withaferin A-specific value. |
| Conditional arithmetic | 18 mg × 0.0521 = 0.9378 mg | About 0.94 mg total withanolides if 18 mg of that material was used. |
| Exact Withaferin A | Cannot be calculated | Requires a specific assay of the relevant material or finished batch. |
The condition matters. The certificate is evidence about a supplier sample or lot under its stated method. It is not a bill of materials, manufacturing record, identity check at receipt, in-process reconciliation or assay of the retail tablets. The correct next evidence is a traceable chain from purchase and dispensing records to the finished batch, supported by a method capable of measuring Withaferin A specifically. Until then, the calculation explains the specification gap without pretending to be a measurement.
02 · Human evidence
People have mainly received extracts, not isolated Withaferin A
The most directly relevant clinical study enrolled 13 people with relapsed, advanced high-grade osteosarcoma in a phase I dose-escalation design. The intervention was not purified Withaferin A. It was a 400 mg ashwagandha root-extract capsule standardized to 4.5% Withaferin A—18 mg of nominal Withaferin A per capsule—processed in clarified butter. Daily cohorts received 72, 108, 144 or 216 mg of nominal Withaferin A.2
No dose-limiting toxicity occurred. Eleven grade 1 or 2 events were recorded; five of 13 participants had grade 1 liver-enzyme elevations, and rash occurred in two. Withaferin A was not detected in plasma with an assay whose lower quantification limit was 50 ng/mL. The trial was small, non-randomized, conducted in a serious cancer population and designed around dose escalation rather than efficacy. Its extract delivered 18 mg nominal Withaferin A in 400 mg of material, which is chemically and quantitatively different from 18 mg of a 5.21%-total-withanolide extract. It cannot validate either the Geroprotect declaration or the conditional 0.94 mg total-withanolide exposure.
A later randomized crossover pharmacokinetic study in 16 healthy volunteers reinforces the preparation problem. Investigators compared two ashwagandha extracts normalized to 185 mg total withanolides: 480 mg of a high-glycoside extract and 7,400 mg of a 2.5% extract. Withaferin A and other withanolides were detected with LC–MS/MS, but the products were not bioequivalent. Their composition and plasma profiles differed substantially despite the same nominal total-withanolide dose.3 This does not tell us what an 18 mg Geroprotect serving delivers. It shows why percentage totals cannot replace ingredient identity and formulation-specific pharmacokinetics.
One open-label safety study gave 18 healthy men 500 mg of a characterized root extract twice daily for 30 days. Each capsule contained at least 7.5 mg total withanolides and measured about 1.995 mg Withaferin A; no adverse events were recorded during the study.4 The sample was small, male-only, short, non-randomized and industry-associated. It is useful preparation-specific tolerability evidence, not proof about isolated Withaferin A, a different 5.21% material or a thirteen-active tablet.
No controlled human healthy-aging trial located for this review tested purified 99% Withaferin A, measured proteostasis target engagement, biological age, healthspan or lifespan. The phase I cancer study is the closest human Withaferin-A-focused experiment, but its intervention remained an enriched botanical extract. That is why the human tier is described as limited rather than absent.
03 · Preclinical mechanisms
Interesting biology, with stress and cytotoxicity kept in view
Withaferin A is electrophilic and can react with susceptible protein thiols. That helps explain its broad laboratory target profile—and why a pathway diagram can look more settled than the biology actually is.
Vimentin. In endothelial-cell and biochemical experiments, Withaferin A covalently modified a cysteine in vimentin, altered filament organization and inhibited capillary growth in a mouse corneal model.5 This makes vimentin a credible molecular target. It does not show regeneration, reversal of epithelial–mesenchymal transition in humans or a longevity outcome.
Hsp90 and protein clients. In pancreatic-cancer cells, a biotinylated probe supported binding at the Hsp90 C-terminal region. Withaferin A disrupted the Hsp90–Cdc37 complex and promoted proteasome-dependent loss of selected Hsp90 client proteins.6 These are anticancer cell and xenograft results. Hsp90 is a central chaperone, so inhibiting it is not automatically “improving folding.” It can destabilize proteins and generate a compensatory stress response.
Proteasome and heat-shock response. Withaferin A inhibited chymotrypsin-like proteasome activity in purified enzyme, prostate-cancer cells and xenografts, with accumulation of ubiquitinated proteins and apoptosis.7 In amphibian kidney epithelial cells, it also produced proteasome inhibition, endoplasmic-reticulum stress and heat-shock-protein accumulation; prior exposure increased thermotolerance in that cell system.8 Hormesis is one possible research interpretation. Another is proteotoxic stress. A consumer claim requires exposure and outcome evidence, not the preferred interpretation of a cell response.
NF-κB and Nrf2. In cell systems, Withaferin A inhibited TNF-induced IKKβ/NF-κB signalling through a redox-sensitive mechanism.9 In a mouse acetaminophen-injury model, it induced Nrf2-dependent cytoprotective genes and protection was lost when Nrf2 signalling was disrupted.10 These findings support mechanistic plausibility, not a demonstrated chronic anti-inflammatory or liver-protective effect in healthy people.
Metabolism. A chemical-signature screen identified Withaferin A as a leptin-sensitizing candidate. Treatment reduced weight and metabolic abnormalities in diet-induced-obese mice, while effects were much smaller in mice deficient in leptin signalling.11 The result is an animal pharmacology finding. It does not establish weight loss, insulin sensitivity or a safe metabolic dose in humans.
The nearest direct longevity experiment used Drosophila melanogaster. Dietary Withaferin A at 10 or 100 µM increased median male lifespan by 7.7% or 9.6%, respectively, but stress-resistance effects varied by sex, age and challenge; some comparisons moved in the unfavorable direction.12 A fly result can prioritize experiments. It cannot support the statement that Withaferin A—or Essentials II—extends human life.
04 · Safety and interactions
Proportionate caution means neither reassurance nor alarm
The current records do not support calling the documented material inert, harmless or incapable of biological activity. A small conditional amount is not the same as zero, and neither a raw-material percentage nor a dose comparison can establish individual safety. At the same time, case reports and high-exposure cancer research should not be projected onto an unmeasured low exposure as if routine harm were expected.
Published liver-injury series concern ashwagandha products, not purified Withaferin A. In an Icelandic and US series, five people developed cholestatic or mixed liver injury after ashwagandha-containing products; no participant developed liver failure, and four recovered after discontinuation, while other supplements complicated attribution in several cases.13 A later Indian series described eight single-ingredient-product cases, including severe outcomes in people with pre-existing chronic liver disease.14 Those reports justify liver-focused caution for ashwagandha products, especially with liver disease or other hepatically relevant substances. They do not identify Withaferin A as the causal molecule or estimate risk at the Geroprotect amount.
Thyroid context is also extract-specific. In a small eight-week randomized trial of 50 people with subclinical hypothyroidism, 600 mg/day ashwagandha root extract changed TSH, T3 and T4 relative to placebo.15 That study was testing a clinical population and does not prove a thyroid effect from an unknown amount of Withaferin A. It does support having the complete formula reviewed when thyroid disease or thyroid medicine is involved.
The phase I cancer trial excluded CYP inducers and inhibitors and cannot answer interaction questions for routine polypharmacy. Withaferin A’s preclinical effects on Hsp90, the proteasome, cytoskeletal proteins and cell death are also reasons not to improvise its use during chemotherapy, radiotherapy or other cancer treatment. People with liver disease, thyroid disease, pregnancy or breastfeeding, or regular prescription medicines should ask a clinician or pharmacist to review the whole formula. This is standard uncertainty management, not a prediction that an interaction will occur.
05 · Formula and quality context
What Geroprotect can say now—and what needs a test
A full six-tablet labelled serving of Essentials II currently lists Withaferin A · 18 mg. The formulation brief specified a nominal 99% Withaferin A material. Those statements record the intended public identity, amount and design purity; they are not a finished-batch assay. The available supplier record does not match that specification: it identifies an ashwagandha extract and a total-withanolide percentage, not a high-purity Withaferin A material.
The defensible response has three parts. First, keep the identity mismatch visible in the evidence record and do not transform a total assay into a molecule-specific number. Second, obtain and reconcile purchasing, dispensing and manufacturing records, then use an appropriate laboratory method on retained finished product if a finished-batch amount is to be stated. Third, replace or reformulate only after the next candidate’s identity, dose basis, analytical method, stability, interactions and relevant market requirements have been reviewed.
The replacement is under review and is deliberately unnamed here. Naming a candidate before the formulation and quality gate closes would turn an internal option into a public promise. The same restraint applies to the rest of the formula: this note does not conclude that the other twenty-five ingredients are verified, exact, unaffected or clinically validated. Each requires its own current, traceable evidence.
Finally, no raw-material certificate should be presented as a finished-product COA. They answer different questions. A raw-material COA may describe the supplier’s tested sample; a finished-product COA should describe the released retail batch under stated methods and acceptance criteria. Traceability is the bridge between them.
Evidence verdict
The specification gap is clear; the finished-batch amount is not
| Statement | Evidence boundary |
|---|---|
| Withaferin A and total withanolides are equivalent | No. One is a molecule; the other is a group assay. |
| Eighteen milligrams of 5.21% extract yields about 0.94 mg | Yes, conditionally—and the result is total withanolides, not Withaferin A. |
| The raw-material certificate proves what is in the finished tablets | No. Finished-batch inclusion and dose require traceability and appropriate finished-product evidence. |
| Withaferin A has interesting proteostasis-related mechanisms | Supported preclinically, often in cancer or injury models; a healthy-human outcome is not established. |
| Ashwagandha clinical trials prove isolated Withaferin A efficacy | No. Extract composition and matrix matter, and the interventions are not interchangeable. |
| The next-batch replacement is decided | No. Candidate review is continuing, and no replacement is named in this edition. |
Questions
Frequently asked questions
Is Withaferin A the same as ashwagandha?
No. Ashwagandha is a plant and its extracts contain many constituents. Withaferin A is one defined withanolide that may be present in varying amounts.
Does 5.21% total withanolides mean 5.21% Withaferin A?
No. A total-withanolide assay combines a group of related molecules. The Withaferin A fraction requires a specific analytical result.
How is the approximately 0.94 mg figure calculated?
It is 18 mg multiplied by 5.21%, or 18 × 0.0521 = 0.9378 mg. It is conditional on 18 mg of the documented extract having been used, and it describes total withanolides—not exact Withaferin A.
Does the supplier COA prove the amount in my bottle?
No. It describes a raw-material sample or lot under the supplier’s stated method. Finished-product inclusion and amount require manufacturing traceability and an appropriate finished-batch assay.
Has isolated Withaferin A been proven to slow human aging?
No. The mechanisms and fly-lifespan result are preclinical. Human studies mainly test complex ashwagandha extracts, and no healthy-human longevity outcome has been established.
What will replace Withaferin A in the next batch?
The replacement is under review. Geroprotect will name it only after the identity, amount, quality documentation, evidence, interaction context and market requirements are resolved.
Primary sources
References
- Girme A, et al. Investigating 11 withanosides and withanolides by UHPLC–PDA and mass-fragmentation studies from ashwagandha (Withania somnifera). ACS Omega. 2020;5:27933–27943. DOI 10.1021/acsomega.0c03266.
- Pires N, et al. Safety and pharmacokinetics of Withaferin-A in advanced-stage high-grade osteosarcoma: a phase I trial. Journal of Ayurveda and Integrative Medicine. 2020;11:68–72. DOI 10.1016/j.jaim.2018.12.008.
- Kim SK, et al. Pharmacokinetics and bioequivalence of Withania somnifera extracts—a double-blind crossover study in healthy adults. Heliyon. 2023;9:e22843. DOI 10.1016/j.heliyon.2023.e22843. Industry-associated study.
- Vaidya VG, et al. Clinical safety and tolerability evaluation of Withania somnifera root extract in healthy human volunteers. Journal of Ayurveda and Integrative Medicine. 2024;15:100859. DOI 10.1016/j.jaim.2023.100859. Small, open-label, industry-associated study.
- Bargagna-Mohan P, et al. The tumor inhibitor and antiangiogenic agent Withaferin A targets the intermediate-filament protein vimentin. Chemistry & Biology. 2007;14:623–634.
- Yu Y, et al. Withaferin A targets heat-shock protein 90 in pancreatic cancer cells. Biochemical Pharmacology. 2010;79:542–551. DOI 10.1016/j.bcp.2009.09.017.
- Yang H, Shi G, Dou QP. The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from Indian winter cherry. Molecular Pharmacology. 2007;71:426–437. DOI 10.1124/mol.106.030015.
- Khan S, Rammeloo AW, Heikkila JJ. Withaferin A induces proteasome inhibition, endoplasmic-reticulum stress, the heat-shock response and acquisition of thermotolerance. PLoS ONE. 2012;7:e50547. DOI 10.1371/journal.pone.0050547.
- Kaileh M, et al. Withaferin A strongly elicits IκB kinase β hyperphosphorylation concomitant with potent inhibition of its kinase activity. Journal of Biological Chemistry. 2007;282:4253–4264.
- Palliyaguru DL, et al. Withaferin A induces Nrf2-dependent protection against liver injury: role of Keap1-independent mechanisms. Free Radical Biology and Medicine. 2016;101:116–128. DOI 10.1016/j.freeradbiomed.2016.10.003.
- Lee J, et al. Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice. Nature Medicine. 2016;22:1023–1032. DOI 10.1038/nm.4145.
- Koval L, et al. Evaluation of the geroprotective effects of Withaferin A in Drosophila melanogaster. Aging. 2021;13:1817–1841. DOI 10.18632/aging.202572.
- Björnsson HK, et al. Ashwagandha-induced liver injury: a case series from Iceland and the US Drug-Induced Liver Injury Network. Liver International. 2020;40:825–829. DOI 10.1111/liv.14393.
- Philips CA, et al. Ashwagandha-induced liver injury: a case series from India and literature review. Hepatology Communications. 2023;7:e0270. Case-series evidence concerning ashwagandha products, not isolated Withaferin A.
- Sharma AK, et al. Efficacy and safety of ashwagandha root extract in subclinical hypothyroid patients: a double-blind, randomized placebo-controlled trial. Journal of Alternative and Complementary Medicine. 2018;24:243–248. DOI 10.1089/acm.2017.0183.










